Shen K, Tian Z, Gao Y, et al. Chinese consensus on the diagnosis and treatment of immunoglobulin light-chain cardiac amyloidosis. Chin Med J (Engl). 2024;137:127–9.

Article  PubMed  Google Scholar 

Gertz MA. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. Am J Hematol. 2022;97:818–29.

Article  CAS  PubMed  Google Scholar 

Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016;68:1323–41.

Article  PubMed  Google Scholar 

Dittloff KT, Iezzi A, Zhong JX, Mohindra P, Desai TA, Russell B. Transthyretin amyloid fibrils alter primary fibroblast structure, function, and inflammatory gene expression. Am J Physiol Heart Circ Physiol. 2021;321:H149-h160.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Humeres C, Frangogiannis NG. Fibroblasts in the Infarcted, Remodeling, and Failing Heart. JACC Basic Transl Sci. 2019;4:449–67.

Article  PubMed  PubMed Central  Google Scholar 

Park S, Nguyen NB, Pezhouman A, Ardehali R. Cardiac fibrosis: potential therapeutic targets. Transl Res. 2019;209:121–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fontana M, Ćorović A, Scully P, Moon JC. Myocardial Amyloidosis: The Exemplar Interstitial Disease. JACC Cardiovasc Imaging. 2019;12:2345–56.

Article  PubMed  Google Scholar 

Palladini G, Merlini G. How I treat AL amyloidosis. Blood. 2022;139:2918–30.

Article  CAS  PubMed  Google Scholar 

Muchtar E, Gertz MA, Kumar SK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129:2111–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palladini G, Schönland S, Merlini G, et al. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J. 2023;13:19.

Article  PubMed  PubMed Central  Google Scholar 

Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16:129.

Article  PubMed  PubMed Central  Google Scholar 

Banypersad SM, Sado DM, Flett AS, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6:34–9.

Article  PubMed  Google Scholar 

Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92.

Article  PubMed  PubMed Central  Google Scholar 

Lurz JA, Luecke C, Lang D, et al. CMR-Derived Extracellular Volume Fraction as a Marker for Myocardial Fibrosis: The Importance of Coexisting Myocardial Inflammation. JACC Cardiovasc Imaging. 2018;11:38–45.

Article  PubMed  Google Scholar 

Li X, Huang S, Miao H, et al. Multiparameter Cardiac Magnetic Resonance to Monitor Therapeutic Effect After Chemotherapy in Light Chain Amyloidosis Patients. JACC Cardiovasc Imaging. 2021;14:1485–7.

Article  PubMed  Google Scholar 

Cuddy SAM, Jerosch-Herold M, Falk RH, et al. Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy. JACC Cardiovasc Imaging. 2022;15:594–603.

Article  PubMed  Google Scholar 

Gertz MA, Dispenzieri A. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA. 2020;324:79–89.

Article  CAS  PubMed  Google Scholar 

Zhang C, Huang X, Li J. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role? Blood Rev. 2017;31:261–70.

Article  CAS  PubMed  Google Scholar 

Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004;94:1008–10.

Article  CAS  PubMed  Google Scholar 

Dorbala S, Vangala D, Bruyere J, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014;2:358–67.

Article  PubMed  PubMed Central  Google Scholar 

Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113:2089–96.

Article  CAS  PubMed  Google Scholar 

Biolo A, Ramamurthy S, Connors LH, et al. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. Circ Heart Fail. 2008;1:249–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanaka K, Essick EE, Doros G, et al. Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis. J Am Heart Assoc. 2013;2:e005868.

Article  PubMed  PubMed Central  Google Scholar 

Siegismund CS, Escher F, Lassner D, et al. Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis. Eur J Heart Fail. 2018;20:751–7.

Article  CAS  PubMed  Google Scholar 

Simon P, Behrens H-M, Kristen A, Röcken C. Myocardial inflammatory cells in cardiac amyloidosis. Sci Rep. 2024;14:23313.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pucci A, Aimo A, Musetti V, et al. Amyloid Deposits and Fibrosis on Left Ventricular Endomyocardial Biopsy Correlate With Extracellular Volume in Cardiac Amyloidosis. J Am Heart Assoc. 2021;10:e020358.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dorbala S. Fibroblast Activation: A Novel Mechanism of Heart Failure in Light Chain Cardiac Amyloidosis? JACC Cardiovasc Imaging. 2022;15:1971–3.

Article  PubMed  Google Scholar 

Antoni G, Lubberink M, Estrada S, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54:213–20.

Article  CAS  PubMed  Google Scholar 

Dorbala S, Kijewski MF. Molecular Imaging of Systemic and Cardiac Amyloidosis: Recent Advances and Focus on the Future. J Nucl Med. 2023;64:20s–8s.

Article  CAS  PubMed  Google Scholar 

Masri A, Bukhari S, Eisele YS, Soman P. Molecular Imaging of Cardiac Amyloidosis. J Nucl Med. 2020;61:965–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Genovesi D, Vergaro G, Giorgetti A, et al. [18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions. JACC Cardiovasc Imaging. 2021;14:246–55.

Article  PubMed  Google Scholar